Cosyntropin: complete guide

Cosyntropin is a synthetic ACTH 1-24 peptide used to screen for adrenal insufficiency, first approved by FDA as Cortrosyn in 1970. This guide covers structure, use and safety.

Complete guide5 min read

Key takeaway

Drugs@FDA lists the original approval of Cortrosyn on April 22, 1970. Cosyntropin has 24 amino acids and a molecular weight of 2,933.4 g/mol. In a pooled diagnostic analysis, the standard cosyntropin test detected 97% of primary adrenal insufficiency at 95% specificity, but only 57% of secondary cases.

At a glance

Article typeComplete guide
Regulatory statusFDA-approved“Drugs@FDA lists the original approval of Cortrosyn on April 22, 1970.” (this article)
ClassMetabolic & weight
Body systemsEndocrine & metabolism
Studies cited1 in this article · 1 across 1 article on Cosyntropin
Related productsIncretin analogs

Cosyntropin is a synthetic peptide made of the first 24 amino acids of ACTH, the pituitary hormone that drives cortisol. It is a diagnostic agent, used to check whether the adrenal glands can respond. This guide covers its structure, mechanism, FDA-labeled use, key evidence and label warnings. Sources were checked on November 17, 2026.

Quick answer: Cosyntropin is a prescription diagnostic agent sold as Cortrosyn and as generics. Its label covers screening for adrenocortical insufficiency in adults and children, together with other tests. It is not a treatment. The label has no boxed warning; hypersensitivity, including anaphylaxis, is the main warning.

Vitrapep does not sell cosyntropin; this page is a reference summary of published research and regulatory information.

What is cosyntropin?

Cosyntropin is a shortened, lab-made copy of adrenocorticotropic hormone (ACTH). The Cortrosyn label says it contains “the first 24 of the 39 amino acids of natural ACTH.” It describes cosyntropin as an open-chain polypeptide and as a synthetic beta 1-24 corticotropin (Cortrosyn label, 2025).

It is a peptide because it is a single chain of 24 amino acids. That is well under FDA’s cutoff for a protein, which is “greater than 40 amino acids in size” (21 CFR 600.3). PubChem lists the formula C136H210N40O31S and a molecular weight of 2,933.4 g/mol (PubChem CID 16129617). Our peptide primer explains the basics.

Drugs@FDA lists the original approval of Cortrosyn (NDA 016750) on April 22, 1970, now held by Amphastar (Drugs@FDA). Current cosyntropin labels, including Cortrosyn and a Sandoz generic, give 2008 as the “Initial U.S. Approval” year. The sources we checked do not explain that difference.

Table 1

Cosyntropin: key facts

Fact Detail
Structure type Linear (open-chain) peptide of 24 amino acids, matching ACTH 1-24
Class Synthetic ACTH fragment; diagnostic agent
Molecular formula C136H210N40O31S
Molecular weight 2,933.4 g/mol
First FDA approval April 22, 1970 (Cortrosyn, NDA 016750); labels state 2008 as initial U.S. approval
Brand names (US) Cortrosyn; generic cosyntropin from Sandoz and others

How does cosyntropin work?

The first 24 amino acids of ACTH carry its activity on the adrenal glands. The Cortrosyn label states: “Cosyntropin exhibits the full corticosteroidogenic activity of natural ACTH.” Its profile is similar to purified natural ACTH, and it stimulates the adrenal cortex to the same maximal extent (Cortrosyn label, 2025).

That makes it a test of adrenal reserve. A healthy adrenal cortex answers the signal by making cortisol. A failing one does not. The label’s warning on diagnostic accuracy notes that cortisol levels drive the diagnosis. Natural ACTH products such as Acthar Gel are a different thing. They are porcine-derived mixtures used as treatments, covered in our corticotropin guide (Acthar label, 2026).

What is cosyntropin approved for?

The Cortrosyn label states that it “is indicated, in combination with other diagnostic tests, for use as a diagnostic agent.” The intended use is “the screening of adrenocortical insufficiency in adults and pediatric patients.” The Sandoz generic label carries the same indication (Sandoz cosyntropin label, 2024). Adrenocortical insufficiency means the adrenal glands do not make enough cortisol.

What does the key evidence show?

Because cosyntropin is a diagnostic, the key question is accuracy: how well does the test sort people with and without adrenal insufficiency? Primary adrenal insufficiency starts in the adrenal glands. Secondary adrenal insufficiency starts in the pituitary, which stops sending enough ACTH.

Pooled diagnostic analysis. A 2003 review searched MEDLINE from 1966 to 2002 and pooled human study data into summary ROC curves. At 95% specificity, the standard cosyntropin test had 97% sensitivity for primary adrenal insufficiency. For secondary adrenal insufficiency, sensitivity fell to 57%. A lower-stimulus version of the test reached 61%. The authors wrote that “the cosyntropin test performs well in patients with primary adrenal insufficiency” (Dorin et al., 2003).

For secondary disease, they advised tests that stimulate the hypothalamus when suspicion is high enough. The label likewise frames cosyntropin as one test used with others.

What side effects does the label list?

The Cortrosyn label has no boxed warning. Its only contraindication is a history of hypersensitivity to cosyntropin or its excipients. Its adverse reactions come from post-approval reports, so the label notes their frequency cannot be reliably estimated. The reported reactions are:

  • anaphylactic reaction;
  • slow or fast heart rate (bradycardia, tachycardia);
  • high blood pressure; and
  • peripheral edema and rash.

The label has two warnings. The first is hypersensitivity, including anaphylaxis. The second is diagnostic inaccuracy: medicines and conditions that change cortisol or cortisol-binding globulin levels can skew results (Cortrosyn label, 2025).

What is cosyntropin’s regulatory status, and how is it used in research?

Cosyntropin is a prescription diagnostic agent in the United States. Cortrosyn is marketed under an NDA; the Sandoz product is an ANDA generic (ANDA 202147). DailyMed lists Cortrosyn from Amphastar, generics from Sandoz and others, and listings from Medical Purchasing Solutions and HealthFirst. It also lists Cosacthen, a veterinary cosyntropin product from Dechra Veterinary Products (DailyMed, 2026). The evidence summarized here comes from human diagnostic studies.

Frequently asked questions about cosyntropin

Is cosyntropin a peptide?

Yes. It is a synthetic 24-amino-acid peptide matching the first 24 amino acids of ACTH.

Is cosyntropin a treatment?

No. Its label covers use as a diagnostic agent to screen for adrenocortical insufficiency, alongside other tests.

When was cosyntropin approved?

Drugs@FDA lists the original approval of Cortrosyn on April 22, 1970.

How is cosyntropin different from Acthar Gel?

Cosyntropin is a synthetic 24-amino-acid fragment used for testing. Acthar Gel is a porcine-derived mixture built around full-length ACTH and used as a treatment.

Does cosyntropin have a boxed warning?

No. Its warnings are hypersensitivity, including anaphylaxis, and factors that can make test results inaccurate.

What to know now

  • Structure: synthetic ACTH 1-24 peptide; C136H210N40O31S; 2,933.4 g/mol.
  • Approval: Cortrosyn, April 22, 1970 (Drugs@FDA); prescription diagnostic only.
  • Mechanism: full corticosteroidogenic activity of natural ACTH on the adrenal cortex.
  • Evidence: 97% sensitivity for primary and 57% for secondary adrenal insufficiency at 95% specificity.
  • Safety: no boxed warning; anaphylaxis and diagnostic inaccuracy are the warnings.

What we’re watching

Further Cortrosyn label revisions on DailyMed, last revised in February 2025. Related guides: corticotropin, pasireotide and secretin, another peptide used as a diagnostic.

More for endocrine & metabolism

All 38 compounds for endocrine & metabolism

Sources: Amphastar Pharmaceuticals 2025, CORTROSYN (cosyntropin) prescribing information; Sandoz Inc 2024, Cosyntropin prescribing information; U.S. Food and Drug Administration. Drugs@FDA: NDA 016750 (CORTROSYN) . Retrieved November 17, Drugs@FDA: NDA 016750 (CORTROSYN); National Center for Biotechnology Information 2026, PubChem compound summary for CID 16129617, cosyntropin; Dorin 2003, Annals of Internal Medicine, 139; Keenova ARD LLC 2026, ACTHAR (repository corticotropin) prescribing information; U.S. National Library of Medicine 2026, DailyMed SPL listing: cosyntropin; Legal Information Institute. 21 CFR § 600.3: Definitions . Cornell Law School. Retrieved November 17, 21 CFR § 600.3: Definitions. All 8 citations

Back to the research library

References

  1. Amphastar Pharmaceuticals, Inc. (2025). CORTROSYN (cosyntropin) prescribing information (revised 2/2025). DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=746856e9-3930-4f6a-b8e6-a03845d6dd0b
  2. Sandoz Inc. (2024). Cosyntropin prescribing information (revised 1/2024; ANDA 202147). DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1342169c-e214-4f22-8363-1fd45b85d1e8
  3. U.S. Food and Drug Administration. Drugs@FDA: NDA 016750 (CORTROSYN). Retrieved November 17, 2026, from https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=016750
  4. National Center for Biotechnology Information. (2026). PubChem compound summary for CID 16129617, cosyntropin. Retrieved November 17, 2026, from https://pubchem.ncbi.nlm.nih.gov/compound/16129617
  5. Dorin, R. I., et al. (2003). Diagnosis of adrenal insufficiency. Annals of Internal Medicine, 139(3), 194-204. https://doi.org/10.7326/0003-4819-139-3-200308050-00009
  6. Keenova ARD LLC. (2026). ACTHAR (repository corticotropin) prescribing information (revised 10/2026). DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7b48ddec-e815-45f4-9ca0-5c0daaf56f30
  7. U.S. National Library of Medicine. (2026). DailyMed SPL listing: cosyntropin. Retrieved November 17, 2026, from https://dailymed.nlm.nih.gov/dailymed/services/v2/spls.json?drug_name=cosyntropin
  8. Legal Information Institute. 21 CFR § 600.3: Definitions. Cornell Law School. Retrieved November 17, 2026, from https://www.law.cornell.edu/cfr/text/21/600.3